Back to Interventions
Substance / Medication

Mipomersen

SNOMED 716221002UMLS C2604635

Overview

Active Ingredient
mipomersen
RxNorm CUI
1367839

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Familial combined hyperlipidemia
Familial multiple lipoprotein-type hyperlipidemia

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

1
Total Trials
0
Recruiting
0
With Results

Recent Trials

Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol

NCT00754039Phase 4Completed129 enrolled
View all 1 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Fogacci Federica, Ferri Nicola, Toth Peter P et al. · Drugs · 2019
PMID: 30989634Meta-Analysis
Mipomersen is a promising therapy in the management of hypercholesterolemia: a meta-analysis of randomized controlled trials.
Li Na, Li Qing, Tian Xia-Qiu et al. · Am J Cardiovasc Drugs · 2014
PMID: 25027352Meta-Analysis
Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
Thomas Gregory S, Cromwell William C, Ali Shariq et al. · J Am Coll Cardiol · 2013
PMID: 24013058RCT
Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins.
Furtado Jeremy D, Wedel Mark K, Sacks Frank M · J Lipid Res · 2012
PMID: 22301884RCTFull text (PMC)
Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial.
Visser Maartje E, Wagener Gilbert, Baker Brenda F et al. · Eur Heart J · 2012
PMID: 22507979RCTFull text (PMC)
Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia.
Reeskamp Laurens F, Kastelein John J P, Moriarty Patrick M et al. · Atherosclerosis · 2019
PMID: 30500603Observational
Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia.
Akdim Fatima, Visser Maartje E, Tribble Diane L et al. · Am J Cardiol · 2010
PMID: 20451687Observational
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.
Raal Frederick J, Santos Raul D, Blom Dirk J et al. · Lancet · 2010
PMID: 20227758Observational
Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia.
Won Jane I, Zhang Jun, Tecson Kristen M et al. · Rev Cardiovasc Med · 2017
PMID: 28509890Case Report
Pharmacogenetics in the Development of Lipid Lowering Medications: Lomitapide & Mipomersen in Clinical Practice.
Marbach Jeffrey A, Thapa Jhapat, Goldenberg Edward et al. · Del Med J · 2015
PMID: 26402926Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Mipomersen (substance)
SNOMED CT
716221002
UMLS CUI
C2604635
RxNorm CUI
1367839

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
1
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.